HK1000697A1 - Use of droloxifene for the treatment of cardiovascular diseases - Google Patents

Use of droloxifene for the treatment of cardiovascular diseases

Info

Publication number
HK1000697A1
HK1000697A1 HK97102010A HK97102010A HK1000697A1 HK 1000697 A1 HK1000697 A1 HK 1000697A1 HK 97102010 A HK97102010 A HK 97102010A HK 97102010 A HK97102010 A HK 97102010A HK 1000697 A1 HK1000697 A1 HK 1000697A1
Authority
HK
Hong Kong
Prior art keywords
droloxifene
treatment
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
HK97102010A
Other languages
English (en)
Inventor
Roland Loser
Michael Schliack
David D Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HK1000697A1 publication Critical patent/HK1000697A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
HK97102010A 1994-07-19 1997-10-23 Use of droloxifene for the treatment of cardiovascular diseases HK1000697A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/276,969 US5441986A (en) 1994-07-19 1994-07-19 Estrogen agonists as remedies for prostate and cardiovascular diseases
PCT/IB1995/000403 WO1996002242A1 (en) 1994-07-19 1995-05-26 Use of droloxifene for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
HK1000697A1 true HK1000697A1 (en) 2002-05-10

Family

ID=23058874

Family Applications (1)

Application Number Title Priority Date Filing Date
HK97102010A HK1000697A1 (en) 1994-07-19 1997-10-23 Use of droloxifene for the treatment of cardiovascular diseases

Country Status (17)

Country Link
US (4) US5441986A (ja)
EP (3) EP0771194A1 (ja)
JP (2) JP2930424B2 (ja)
KR (2) KR100212352B1 (ja)
CN (2) CN1152868A (ja)
AU (2) AU694220B2 (ja)
CA (2) CA2195213C (ja)
FI (2) FI970215A (ja)
HK (1) HK1000697A1 (ja)
HU (2) HUT77391A (ja)
IL (2) IL114585A (ja)
MX (2) MX9700534A (ja)
MY (1) MY113079A (ja)
NZ (2) NZ285158A (ja)
TW (1) TW403649B (ja)
WO (2) WO1996002243A1 (ja)
ZA (2) ZA955963B (ja)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
ATE377418T1 (de) 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
US5726207A (en) * 1996-02-28 1998-03-10 Pfizer Inc. Protection of ischemic myocardium against reperfusion damage
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5733937A (en) * 1996-02-28 1998-03-31 Pfizer Inc. Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
IL120269A0 (en) * 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6114395A (en) * 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
FI982733A (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf
AU5957500A (en) 1999-07-06 2001-01-22 Endorecherche Inc. Methods of treating and/or suppressing weight gain
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
RU2480207C2 (ru) * 2006-05-22 2013-04-27 Хормос Медикал Лтд. Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
JP5363344B2 (ja) * 2007-02-14 2013-12-11 ホルモス メディカル リミテッド 治療に有用なトリフェニルブテン誘導体の調製方法
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
FR2619383B1 (fr) * 1987-08-12 1989-12-08 Inst Vaisseaux Sang Proteine a activite vasculaire, derivee des monocytes et ses analogues, procede pour son extraction et leurs utilisations en therapeutique et pour la preparation d'anticorps
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
DE4401554A1 (de) * 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases

Also Published As

Publication number Publication date
NZ285159A (en) 2000-10-27
AU2416995A (en) 1996-02-16
KR970704429A (ko) 1997-09-06
MY113079A (en) 2001-11-30
WO1996002242A1 (en) 1996-02-01
CN1076967C (zh) 2002-01-02
MX9700534A (es) 1997-04-30
EP1029540A3 (en) 2001-05-16
FI970215A0 (fi) 1997-01-17
FI970214A0 (fi) 1997-01-17
HU9700163D0 (en) 1997-03-28
KR100212352B1 (ko) 1999-08-02
IL114586A (en) 2000-06-29
JPH09507859A (ja) 1997-08-12
AU689257B2 (en) 1998-03-26
JPH09507860A (ja) 1997-08-12
FI970214A (fi) 1997-01-17
ZA955964B (en) 1997-01-20
FI970215A (fi) 1997-01-17
JP2930424B2 (ja) 1999-08-03
CN1153473A (zh) 1997-07-02
US5441986A (en) 1995-08-15
KR970704430A (ko) 1997-09-06
CA2195093A1 (en) 1996-02-01
CN1152868A (zh) 1997-06-25
KR100221854B1 (ko) 1999-09-15
CA2195213A1 (en) 1996-02-01
WO1996002243A1 (en) 1996-02-01
ZA955963B (en) 1997-01-20
AU2417095A (en) 1996-02-16
EP0769941A1 (en) 1997-05-02
IL114586A0 (en) 1995-11-27
EP0771194A1 (en) 1997-05-07
MX9700538A (es) 1997-04-30
CA2195093C (en) 2000-03-07
AU694220B2 (en) 1998-07-16
HUT77391A (hu) 1998-04-28
CA2195213C (en) 2000-03-14
US5852059A (en) 1998-12-22
NZ285158A (en) 2000-07-28
HUT77392A (hu) 1998-04-28
EP1029540A2 (en) 2000-08-23
US5827892A (en) 1998-10-27
TW403649B (en) 2000-09-01
HU9700162D0 (en) 1997-03-28
IL114585A0 (en) 1995-11-27
IL114585A (en) 2000-01-31
US5902830A (en) 1999-05-11

Similar Documents

Publication Publication Date Title
HK1000697A1 (en) Use of droloxifene for the treatment of cardiovascular diseases
ZA95878B (en) Therapeutic guanidines
EP0808324A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CARDIOVASCULAR DISEASES
ZA953256B (en) Skin treatment composition
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
ZA954984B (en) Compositions and methods for the treatment of tumors
GB9414157D0 (en) Medical use
GB9410512D0 (en) Novel treatment
ZA952121B (en) Skin treatment composition
IL115224A0 (en) Preparations for use in the treatment of osteoporosis
EP0981357A4 (en) METHODS AND COMPOSITIONS APPLICABLE TO THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS
GB9510162D0 (en) Compositions for the treatment of skin conditions
GB9518887D0 (en) Treatment of muscular disorders
GB9411635D0 (en) Novel treatment
EP0755262A4 (en) PNEUMOPATHY TREATMENT COMPOSITION
EP0724842A3 (en) Preparation for the treatment of obesity
GB9405046D0 (en) Skin treatment composition
ZA953237B (en) Medical treatment
EP0979234A4 (en) METHODS AND COMPOSITIONS APPLICABLE TO THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS
EP0579077A3 (en) 1,3,4-thiadiazinones for the treatment of cardiovascular diseases
IL119990A0 (en) Topical compositions for the treatment of skin diseases
SI0928193T1 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
IL106917A0 (en) Compositions for the treatment of skin disorders
GB9421398D0 (en) Medical treatment
ZA951421B (en) Medical treatment

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20050526